Education
About Us
Working with TipRanks
Follow Us
Allakos Inc (ALLK)
NASDAQ:ALLK
ALLK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.23 - $1.56
Previous CloseN/A
Volume85.32K
Average Volume (3M)969.72K
Market Cap
$21.67M
Enterprise Value$4.44M
Total Cash (Recent Filing)$17.75M
Total Debt (Recent Filing)$4.16M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 07, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding90,203,250
10 Day Avg. Volume697,627
30 Day Avg. Volume969,717
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$0.35Price Target Upside52.17% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Allakos News
PremiumCompany Announcements
Allakos Reports Q4 2024 Results Amid Strategic Shift
---
Bulls Say, Bears Say
Bulls Say
Cash ReservesThe company ended the quarter with a substantial amount of cash and equivalents.
Financial PerformanceALLK reported a net income for the quarter, reflecting a stable financial position despite challenges.
Bears Say
Clinical Trial OutcomeAK006 failed to demonstrate therapeutic activity vs. placebo, and that further development of AK006 is being discontinued.
Restructuring CostsThere are significant wind down costs related to shutting down the AK006 program, severance payments, and contractual payments to vendors.
Workforce ReductionThe Allakos workforce is being reduced by approximately 75%.
---
Ownership Overview
9.07% Insiders
10.53% Mutual Funds
55.63% Other Institutional Investors
20.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLK FAQ
What was Allakos Inc’s price range in the past 12 months?
Allakos Inc lowest stock price was $0.23 and its highest was $1.55 in the past 12 months.
What is Allakos Inc’s market cap?
Allakos Inc’s market cap is $21.67M.
When is Allakos Inc’s upcoming earnings report date?
Allakos Inc’s upcoming earnings report date is May 07, 2025 which is in 40 days.
How were Allakos Inc’s earnings last quarter?
Allakos Inc released its earnings results on Mar 12, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.171 by $0.171.
Is Allakos Inc overvalued?
According to Wall Street analysts Allakos Inc’s price is currently Undervalued.
Does Allakos Inc pay dividends?
Allakos Inc does not currently pay dividends.
What is Allakos Inc’s EPS estimate?
Allakos Inc’s EPS estimate is -0.29.
How many shares outstanding does Allakos Inc have?
Allakos Inc has 90,203,250 shares outstanding.
What happened to Allakos Inc’s price movement after its last earnings report?
Allakos Inc reported an EPS of $0 in its last earnings report, beating expectations of -$0.171. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Allakos Inc?
Currently, no hedge funds are holding shares in ALLK
---
Allakos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.35 (52.17% Upside)
$0.35 (52.17% Upside)
Blogger Sentiment
Bearish
ALLK Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 885.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.17%
12-Months-Change
Fundamentals
Return on Equity
-93.54%
Trailing 12-Months
Asset Growth
-60.35%
Trailing 12-Months
Company Description
Allakos Inc
Allakos Inc. is a biotechnology company that focuses on the development of therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company's primary product candidate is lirentelimab (AK002), designed to target specific immune cells implicated in various diseases. Allakos operates within the healthcare sector, specifically in the biopharmaceutical industry, where it seeks to address unmet medical needs through innovative biologic treatments.
---
ALLK Stock 12 Month Forecast
Average Price Target
$0.35
▲(52.17% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
AnaptysBio
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering ALLK
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-15.60%
assigned a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -15.60% per trade.
---